Charmacy Pharmaceutical (SEHK:2289) - Aktienkurs, Nachrichten und Analyse

Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

2289 Aktienübersicht

Charmacy Pharmaceutical Co., Ltd. ist im Arzneimittelvertrieb in der Volksrepublik China tätig.

2289 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	2/6
Financial Health	2/6
Dividends	2/6

Belohnungen

Risikoanalyse

Zinszahlungen sind nicht ausreichend durch Erträge gedeckt

Stark schwankender Aktienkurs in den letzten 3 Monaten

Die Gewinnspannen (1.2%) sind niedriger als im Vorjahr (2.2%)

Die Dividende von 3.72% ist durch den Cashflow nicht ausreichend gedeckt.

Charmacy Pharmaceutical Co., Ltd. Wettbewerber

Guanze Medical Information Industry (Holding)

SEHK:2427

HK$959.5m

IVD Medical Holding

SEHK:1931

HK$1.8b

Sinco Pharmaceuticals Holdings

SEHK:6833

HK$473.7m

Shanghai Pioneer Holding

SEHK:1345

HK$2.3b

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Charmacy Pharmaceutical
Historical stock prices
Current Share Price	HK$9.50
52 Week High	HK$20.00
52 Week Low	HK$5.90
Beta	-0.38
1 Month Change	-32.14%
3 Month Change	-16.52%
1 Year Change	18.75%
3 Year Change	57.81%
5 Year Change	29.25%
Change since IPO	18.75%

Aktuelle Nachrichten und Updates

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

May 13

There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

Apr 24

Recent updates

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

May 13

There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

Apr 24

Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jan 19

These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

Oct 25

If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

Sep 17

Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

May 02

What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Mar 15

Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

Feb 17

We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Jan 27

Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

Jan 09

What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Dec 22

Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

Nov 29

Aktionärsrenditen

	2289	HK Healthcare	HK Markt
7D	8.0%	-2.9%	-2.1%
1Y	18.8%	-20.9%	5.6%

Rendite im Vergleich zur Industrie: 2289 übertraf die Branche Hong Kong Healthcare, die im vergangenen Jahr eine Rendite von -21.6 erzielte.

Rendite vs. Markt: 2289 übertraf den Markt Hong Kong, der im vergangenen Jahr eine Rendite von 2.7 erzielte.

Preisvolatilität

Is 2289's price volatile compared to industry and market?
2289 volatility
2289 Average Weekly Movement	19.7%
Healthcare Industry Average Movement	6.7%
Market Average Movement	7.3%
10% most volatile stocks in HK Market	15.6%
10% least volatile stocks in HK Market	3.7%

Stabiler Aktienkurs: 2289Der Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: 2289Die wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 13% auf 20% gestiegen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1984	831	Chuanglong Yao	www.chmyy.com

Charmacy Pharmaceutical Co., Ltd. ist im pharmazeutischen Vertriebsgeschäft in der Volksrepublik China tätig. Das Unternehmen vertreibt westliche Arzneimittel, chinesische Patentarzneimittel, Gesundheitsprodukte und damit zusammenhängende pharmazeutische Beratungsdienste an nachgelagerte Vertriebsunternehmen und Einzelhandelsgeschäfte. Außerdem betreibt es Charmacy e-Medicine, eine B2B-E-Commerce-Plattform für Online-Bestellungen, Anfragen und Zahlungen usw.

Charmacy Pharmaceutical Co., Ltd.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Charmacy Pharmaceutical im Vergleich zum Marktanteil des Unternehmens?
2289 grundlegende Statistiken
Marktanteil	HK$1.03b
Gewinn(TTM)	HK$55.49m
Umsatz(TTM)	HK$4.76b

18.5x

Kurs-Gewinn-Verhältnis

0.2x

Kurs-Umsatz-Verhältnis

Ist 2289 zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
2289 Gewinn- und Verlustrechnung (TTM)
Einnahmen	CN¥4.40b
Kosten der Einnahmen	CN¥4.12b
Bruttogewinn	CN¥288.38m
Sonstige Ausgaben	CN¥237.04m
Umsatz	CN¥51.34m

Zuletzt gemeldete Gewinne

Dec 31, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	0.48
Bruttomarge	6.55%
Nettogewinnspanne	1.17%
Schulden/Eigenkapital-Verhältnis	223.7%

Wie hat sich 2289 auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

3.4%

Aktuelle Dividendenrendite

63%

Ausschüttungsquote

2289 Aktienübersicht

Belohnungen

Risikoanalyse

Charmacy Pharmaceutical Co., Ltd. Wettbewerber

SEHK:2427

HK$959.5m

SEHK:1931

HK$1.8b

SEHK:6833

HK$473.7m

SEHK:1345

HK$2.3b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Investor sentiment deteriorates as stock falls 34%

Upcoming dividend of CN¥0.30 per share

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

New major risk - Share price stability

Investor sentiment improves as stock rises 41%

Recent updates

Investor sentiment deteriorates as stock falls 34%

Upcoming dividend of CN¥0.30 per share

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

New major risk - Share price stability

Investor sentiment improves as stock rises 41%

New major risk - Financial position

Charmacy Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 10 July 2024

Charmacy Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

Charmacy Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Investor sentiment deteriorates as stock falls 17%

Investor sentiment deteriorates as stock falls 18%

These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

Investor sentiment improves as stock rises 31%

Investor sentiment improves as stock rises 19%

New major risk - Earnings quality

If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

First half 2023 earnings released: EPS: CN¥0.24 (vs CN¥0.19 in 1H 2022)

Investor sentiment improves as stock rises 23%

Charmacy Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 26, 2023

Upcoming dividend of HK$0.50 per share at 6.0% yield

Charmacy Pharmaceutical Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2022, Payable on 31 July 2023

Charmacy Pharmaceutical Co., Ltd. Announces Board Changes

Upcoming dividend of CN¥0.45 per share at 6.2% yield

Charmacy Pharmaceutical Co., Ltd. Announces Ordinary Final Dividend for the Year Ended 31 December 2022, Payable on July 31, 2023

Charmacy Pharmaceutical Co., Ltd. Provides Financial Guidance for the 11 Months Ended 30 November 2022

Less than half of directors are independent

Less than half of directors are independent

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.24 in 1H 2021)

Charmacy Pharmaceutical Co., Ltd. to Report First Half, 2022 Results on Aug 31, 2022

Charmacy Pharmaceutical Co., Ltd. Announces Executive Changes

Investor sentiment improved over the past week

Insufficient new directors

Charmacy Pharmaceutical Co., Ltd. Announces Change in Board of Directors and Composition of Board Committees

Full year 2021 earnings released

Charmacy Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on Mar 31, 2022

Investor sentiment deteriorated over the past week

Charmacy Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Ended 31 December 2021

Investor sentiment improved over the past week

First half 2021 earnings released: EPS CN¥0.24 (vs CN¥0.29 in 1H 2020)

First half 2021 earnings released: EPS CN¥0.24 (vs CN¥0.29 in 1H 2020)

Charmacy Pharmaceutical Co., Ltd. to Distribute the Final Dividend for the Year Ended 31 December 2020

Upcoming dividend of CN¥0.20 per share

Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

Full year 2020 earnings released: EPS CN¥0.38 (vs CN¥0.37 in FY 2019)

Full year 2020 earnings released

What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Charmacy Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day low: HK$4.40

Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

New 90-day low: HK$4.43

We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

Investor sentiment improved over the past week

What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

First half earnings released

New 90-day low: HK$4.49

Erträge & Einnahmen